There are only two reasons to stop a clinical trial in the middle, Bob Seevers, a former FDA reviewer, now a regulatory consultant, tells Outside Run
J Pharmacol Exp Ther 282(3):15331540 Thompson RA, Isin EM, Li Y, Weidolf L, Page K, Wilson I, Swallow S, Middleton B, Stahl S, Foster AJ, Dolgos H, Weaver R, Kenna JG (2012) In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs
Lionetti E, Dominijanni V, Iasevoli M et al (2023) Effects of the supplementation with a multispecies probiotic on clinical and laboratory recovery of children with newly diagnosed celiac disease: a randomized, placebo-controlled trial
I don't like fish at all
PMID: 34 SteffanBNTownsendEADenlingerLCJohanssonMW